Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection

Permanent URI for this collectionhttps://hdl.handle.net/11147/7148

Browse

Filters

2008 - 200912020 - 20212

Settings

Subject: search.filters.subject.Combination therapy

Search Results

Now showing 1 - 3 of 3
  • Book Part
    Citation - Scopus: 20
    Flavonoids in Cancer Therapy: Current and Future Trends
    (Elsevier, 2020) Gürler,S.B.; Kiraz,Y.; Baran,Y.
    Flavonoids are a family of polyphenolic photochemical that are naturally found in plants. Flavonoids have been widely studied due to the curiosity of scientists about the implementation of nature to human health. These experimental and epidemiological studies showed that flavonoids have beneficial effects such as antioxidation, antiinflammation, antiplatelet, antiallergic, antiaging, antidiabetic, and anticarcinogenic activity. They can also interact with and regulate cellular proteins, transcription factors, and signaling enzymes at the molecular level. Cancer is one of the most common problems in human health and millions of people die due to cancer every year. Due to the lack of completely efficient therapies for most cancer patients, new approaches should be discovered. Flavonoids have been investigated and many studies have confirmed their importance as a therapy option in many diseases. In this chapter we review the use of flavonoids as therapeutical agents and prevention for cancer, including the recent studies as well as future perspectives in the field. © 2020 Elsevier Inc. All rights reserved.
  • Article
    Citation - WoS: 43
    Citation - Scopus: 61
    Current Status and Perspectives of Protease Inhibitors and Their Combination With Nanosized Drug Delivery Systems for Targeted Cancer Therapy
    (Dove Medical Press Ltd, 2021) Rudzinska, Magdalena; Dağlıoğlu, Cenk; Savvateeva, Lyudmila, V; Kaci, Fatma Necmiye; Antoine, Rodolphe; Zamyatnin, Andrey A., Jr.
    In cancer treatments, many natural and synthetic products have been examined; among them, protease inhibitors are promising candidates for anti-cancer agents. Since dysregulated proteolytic activities can contribute to tumor development and metastasis, antagonization of proteases with tailored inhibitors is an encouraging approach. Although adverse effects of early designs of these inhibitors disappeared after the introduction of next-generation agents, most of the proposed inhibitors did not pass the early stages of clinical trials due to their nonspecific toxicity and lack of pharmacological effects. Therefore, new applications that modulate proteases more specifically and serve their programmed way of administration are highly appreciated. In this context, nanosized drug delivery systems have attracted much attention because preliminary studies have demonstrated that the therapeutic capacity of inhibitors has been improved significantly with encapsulated formulation as compared to their free forms. Here, we address this issue and discuss the current application and future clinical prospects of this potential combination towards targeted protease-based cancer therapy.
  • Article
    Citation - WoS: 11
    Citation - Scopus: 16
    Bisphosphonate Treatment and Radiotherapy in Metastatic Breast Cancer
    (Humana Press, 2008) Ural, Ali Uğur; Avcu, Ferit; Baran, Yusuf
    Patients with advanced breast cancer frequently develop metastasis to bone. Bone metastasis results in intractable pain and high risk of pathologic fractures due to osteolysis. The treatment of breast cancer patients with bone metastases requires a multidisciplinary approach. Radiotherapy is an established treatment for metastatic bone pain. It may be delivered either as a localized low dose treatment for localized bone pain or systemically for more widespread symptoms. Bisphosphonates have been shown to reduce morbidity and bone pain from bone metastases when given to patients with metastatic bone disease. In vivo studies indicate that early bisphosphonates administration in combination with radiotherapy improves remineralization and restabilization of osteolytic bone metastases in animal tumor models. This review focused on a brief discussion about biology of bone metastases, the effects of radiotherapy and bisphosphonate therapy, and possible mechanisms of combination therapy in metastatic breast cancer patients.